Unlock instant, AI-driven research and patent intelligence for your innovation.

Protease inhibitors for use in treatment of psoriasis

An inhibitor, psoriasis technology, applied in the fields of peptide/protein components, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve problems such as skin deficiency

Inactive Publication Date: 2001-11-14
BIOTECHNOLOGY AUSTRALIA PTY LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

U-PA and t-PA Immunoreactivity in Psoriatic Plaques in Biopsies of 40 Psoriasis Patients Before and After Topical (Anthralin, Corticosteroids) and Systemic (PUVA) Treatment , but is absent in normal and treated clean skin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protease inhibitors for use in treatment of psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1: Topical Application of PAI-2 Gel (1 mg / ml) for the Treatment of Psoriasis A. Basic Study Design

[0038] A double-blind, placebo-controlled randomized study was conducted to determine the safety, tolerability and efficacy of topical PAI-2 gel in the treatment of mild to moderate psoriasis. The total number of cases studied was 22: 13 males and 9 females, with a mean age of 42 years (range, 18-64 years). The average disease duration of the enrolled patients was 17 years (range, 3-34 years). Of the 22 patients in the trial, 14 patients had not received treatment for their test lesions before starting the trial, and 8 patients had to discontinue treatment for their lesions.

[0039] 14 days of treatment for psoriatic plaques. On each arm, one lesion was stripped before treatment (day 0) and repeated on day 7 after initiation of treatment. Tinea plaques were peeled off by repeated (10) applications and removal of adhered dressings. Each patient in the study w...

Embodiment 2

[0131] Example 2: Preparation of PAI-2-containing gel and measurement of PAI-2 release

[0132] In these experiments, the PAI-2-containing gel was placed on top of a two-chambered tube. The bottom layer contains buffer, and a microporous membrane separates the two chambers. The release of PAI-2 from the gel was indicated by the presence of PAI-2 in the bottom layer and was monitored with a PAI-2 activity assay.

[0133] The table below reflects the improved properties of the new PAI-2 gel formulation. The release of PAI-2 from the gel was enhanced in figure 1 described in.

[0134] Clarity of PAI-2 Gel Formulations

[0135] Excipient Polymer Concentration (%) Placebo None Genapol PFIO Tween 80Carbopol 971P 0.5 Clear S.O Clear Clear

[0136] 1.0 Clear S.O Clear Clear Carbopol 974P 0.5 Clear opal. S.O S.O

[0137] 1.0 clear cloudy opal. S.OCarbopol 981 0.5 clear S.O clear clear

[0138] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Psoriasis may be treated by topical administration of a urokinase inhibitor, such as PAI-2, or a combination of protease inhibitors, such as PAI-2 with other serine protease inhibitors and / or with protease inhibitors such as inhibitors of metalloproteinases, acid proteases, and thiol proteases.

Description

Background of the invention [0001] Psoriasis is a chronic skin disorder characterized by thickened, inflamed erythema and scaly skin. Psoriasis afflicts about 2% of the population. The disease usually starts early in adult life, but it can also occur in young adults or older adults. The disease varies in severity and is often characterized by alternating remissions and flare-ups. In more severe cases, psoriasis can affect up to 90 percent of the skin and can be life-threatening. [0002] At the cellular level, psoriasis is characterized by excessive proliferation of epidermal keratinocytes, accompanied by infiltration of T lymphocytes and other immune system cells, which lead to inflammation similar to autoimmune diseases. The epidermal replacement time for keratinocytes to travel from the basal cell layer to the stratum corneum is normally 14 days, during which keratinocytes undergo a complex series of gene expression changes that lead to cell death - "terminal differentia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K38/55A61K38/57A61K45/00A61K47/10A61K47/34A61K47/48A61P17/06
CPCA61K38/57A61P17/06
Inventor C·L·邦恩P·J·夏普
Owner BIOTECHNOLOGY AUSTRALIA PTY LTD